Benefit–risk of voxelotor, crizanlizumab, and l-glutamine in sickle cell disease: A systematic review. // The American Journal of the Medical Sciences. – URL: https://www.sciencedirect.com/science/article/pii/S0002962926003216?dgcid=rss_sd_all
Benefit–risk of voxelotor, crizanlizumab, and l-glutamine in sickle cell disease: A systematic review. The American Journal of the Medical Sciences. https://www.sciencedirect.com/science/article/pii/S0002962926003216?dgcid=rss_sd_all
“Benefit–risk of voxelotor, crizanlizumab, and l-glutamine in sickle cell disease: A systematic review.” The American Journal of the Medical Sciences.
@article{article67746,
title = {Benefit–risk of voxelotor, crizanlizumab, and l-glutamine in sickle cell disease: A systematic review},
journal = {The American Journal of the Medical Sciences},
url = {https://www.sciencedirect.com/science/article/pii/S0002962926003216?dgcid=rss_sd_all}
}